BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 19221150)

  • 1. Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer.
    Chen H; Horita N; Ito K; Hara Y; Kobayashi N; Kaneko T
    Transl Lung Cancer Res; 2020 Aug; 9(4):1333-1342. PubMed ID: 32953508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.
    Cooper K; Tappenden P; Cantrell A; Ennis K
    Br J Cancer; 2020 Nov; 123(11):1686-1696. PubMed ID: 32913287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
    Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
    BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
    Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
    PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
    MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer.
    Kim MH; Lee JS; Mok JH; Lee K; Kim KU; Park HK; Kim SJ; Lee MK
    Cancer Res Treat; 2014 Apr; 46(2):165-71. PubMed ID: 24851108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert perspectives on biosimilar monoclonal antibodies in breast cancer.
    Cortés J; Curigliano G; Diéras V
    Breast Cancer Res Treat; 2014 Apr; 144(2):233-9. PubMed ID: 24562824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung cancer stem cells: a biological and clinical perspective.
    Koren A; Motaln H; Cufer T
    Cell Oncol (Dordr); 2013 Jul; 36(4):265-75. PubMed ID: 23900738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.
    Ochi N; Hotta K; Takigawa N; Oze I; Fujiwara Y; Ichihara E; Hisamoto A; Tabata M; Tanimoto M; Kiura K
    PLoS One; 2012; 7(8):e42798. PubMed ID: 22880112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.
    Hotta K; Kiura K; Fujiwara Y; Takigawa N; Hisamoto A; Ichihara E; Tabata M; Tanimoto M
    PLoS One; 2011; 6(11):e26646. PubMed ID: 22114662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Implications of modern anticancer therapies for palliative care concepts].
    Alt-Epping B; Nauck F
    Schmerz; 2010 Dec; 24(6):633-41. PubMed ID: 20882301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.
    Hotta K; Kiura K; Fujiwara Y; Takigawa N; Oze I; Ochi N; Tabata M; Tanimoto M
    Ann Oncol; 2009 May; 20(5):829-34. PubMed ID: 19221150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive-stage small-cell lung cancer--moving beyond response rate?
    Ferraldeschi R; Lorigan P
    Ann Oncol; 2009 May; 20(5):801-2. PubMed ID: 19403933
    [No Abstract]   [Full Text] [Related]  

  • 15. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
    Oze I; Hotta K; Kiura K; Ochi N; Takigawa N; Fujiwara Y; Tabata M; Tanimoto M
    PLoS One; 2009 Nov; 4(11):e7835. PubMed ID: 19915681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.
    Hotta K; Fujiwara Y; Kiura K; Takigawa N; Tabata M; Ueoka H; Tanimoto M
    J Thorac Oncol; 2007 May; 2(5):402-7. PubMed ID: 17473655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
    Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for small-cell lung cancer.
    Metro G; Cappuzzo F
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):591-606. PubMed ID: 19694501
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.